Next Article in Journal
PLGA Biodegradable Nanoparticles Containing Perphenazine or Chlorpromazine Hydrochloride: Effect of Formulation and Release
Next Article in Special Issue
Reduced 5-Methylcytosine Level as a Potential Progression Predictor in Patients with T1 or Non-Invasive Urothelial Carcinoma
Previous Article in Journal / Special Issue
Emerging Biomarkers in Heart Failure and Cardiac Cachexia
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2014, 15(12), 23897-23908;

The Promise of Novel Molecular Markers in Bladder Cancer

Departments of Urology and Molecular Biochemistry, University of Kentucky College of Medicine, Lexington, KY 40536, USA
Author to whom correspondence should be addressed.
Received: 18 September 2014 / Revised: 25 November 2014 / Accepted: 11 December 2014 / Published: 22 December 2014
(This article belongs to the Special Issue Emerging Classes of Biomarkers for Molecular Diagnostics)
Full-Text   |   PDF [677 KB, uploaded 22 December 2014]


Bladder cancer is the fourth most common malignancy in the US and is associated with the highest cost per patient. A high likelihood of recurrence, mandating stringent surveillance protocols, has made the development of urinary markers a focus of intense pursuit with the hope of decreasing the burden this disease places on patients and the healthcare system. To date, routine use of markers is not recommended for screening or diagnosis. Interests include the development of a single urinary marker that can be used in place of or as an adjunct to current screening and surveillance techniques, as well identifying a molecular signature for an individual’s disease that can help predict progression, prognosis, and potential therapeutic response. Markers have shown potential value in improving diagnostic accuracy when used as an adjunct to current modalities, risk-stratification of patients that could aid the clinician in determining aggressiveness of surveillance, and allowing for a decrease in invasive surveillance procedures. This review discusses the current understanding of emerging biomarkers, including miRNAs, gene signatures and detection of circulating tumor cells in the blood, and their potential clinical value in bladder cancer diagnosis, as prognostic indicators, and surveillance tools, as well as limitations to their incorporation into medical practice. View Full-Text
Keywords: bladder cancer; miRNA; tumor markers; urinary markers; urothelial carcinoma bladder cancer; miRNA; tumor markers; urinary markers; urothelial carcinoma
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Miremami, J.; Kyprianou, N. The Promise of Novel Molecular Markers in Bladder Cancer. Int. J. Mol. Sci. 2014, 15, 23897-23908.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top